Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Prandin, Gluconorm, NovoNorm
Repaglinide is a short-acting oral antidiabetic drug in the meglitinide class. It works by stimulating insulin release from the pancreas, helping to lower blood glucose levels after meals. It is primarily used for type 2 diabetes mellitus in conjunction with diet and exercise, and is often prescribed when other oral medications like metformin are not sufficient or tolerated. Repaglinide is not a sulfonylurea but shares a similar mechanism of action by binding to and closing ATP-sensitive potassium channels in pancreatic beta cells, leading to depolarization and insulin secretion.
For the treatment of type 2 diabetes mellitus, specifically to control postprandial blood glucose levels.
Outcome:
Increased repaglinide levels and risk of hypoglycemia.
Mechanism:
Gemfibrozil inhibits CYP2C8, the primary enzyme metabolizing repaglinide.
Outcome:
Masking of hypoglycemia symptoms.
Mechanism:
Beta-adrenergic blockade.
Outcome:
No clinically significant interaction expected.
Mechanism:
Different metabolic pathways.
Most likely new formulation: sustained-release repaglinide (Year 2026, 60% confidence)
Based on current usage trends and clinical trial data, the likelihood of repaglinide remaining a viable treatment option for type 2 diabetes is approximately 85% over the next 5 years.
Antidiabetic, Meglitinide
Meglitinide